Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: Search for Biomarkers associated with gastro-intestinal toxicity

Current Topics in Medicinal Chemistry

Volumn 12, Issue 15, 2012, Pages 1713-1719

  Woloch, Christian ^a   Di Paolo, Antonello ^b   Marouani, Hafedh ^a   Bocci, Guido ^b   Ciccolini, Joseph ^a,c   Lacarelle, Bruno ^c   Danesi, Romano ^b   Iliadis, Athanassios ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b UNIVERSITY OF PISA   (Italy)

^c TIMONE HOSPITAL   (France)

Author keywords

5 FDHU; 5 FU; Logistic regression; Mixture model; Modeling; Population analysis; Tolerability

Indexed keywords

BIOLOGICAL MARKER; DIHYDROFLUOROURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID;

ADJUVANT THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CANCER ADJUVANT THERAPY; CANCER PATIENT; COLORECTAL CANCER; COMPUTER PROGRAM; COVARIANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFORMATION PROCESSING; LEAN BODY WEIGHT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHENOTYPE; PREDICTION; RETROSPECTIVE STUDY; STOMATITIS; VOMITING; WORLD HEALTH ORGANIZATION;

AGED; BIOLOGICAL MARKERS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DIARRHEA; FEMALE; FLUOROURACIL; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NAUSEA; RETROSPECTIVE STUDIES; VOMITING;

EID: 84867559664     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612803531414     Document Type: Article

References (20)

1. Diasio, R.B. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology, 2001, 15(1 Suppl 2), 21-26.
2. Mercier, C.; Ciccolini, J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5- fluorouracil/capecitabine therapy. Clin. Colorectal Cancer, 2006, 6(4), 288-296.
3. Di Paolo, A.; Danesi, R.; Falcone, A.; Cionini, L.; Vannozzi, F.; Masi, G.; Allegrini G.; Mini, E.; Bocci, G.; Conte, P.F.; Del Tacca, M. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann. Oncol., 2001, 12(9), 1301-1306.
4. Ciccolini, J.; Mercier, C.; Evrard, A.; Dahan, L.; Boyer, J.C.; Duffaud, F.; Richard, K.; Blanquicett, C.; Milano, G.; Blesius, A.; Durand, A.; Seitz, J.F.; Favre, R.; Lacarelle, B. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther. Drug Monit., 2006, 28(5), 678-685.
5. Bocci, G.; Barbara, C.; Vannozzi, F.; Di Paolo, A.; Melosi, A.; Barsanti, G.; Allegrini, G.; Falcone, A.; Del Tacca, M.; Danesi, R. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin. Pharmacol. Ther., 2006, 80(4), 384-395.
6. Schwab, M.; Zanger, U.M.; Marx, C.; Schaeffeler, E.; Klein, K.; Dippon, J.; Kerb, R.; Blievernicht, J.; Fischer, J.; Hofmann, U.; Bokemeyer, C.; Eichelbaum, M. German 5-FU Toxicity Study Group. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol., 2008, 26(13), 2131-2138.
7. Ciccolini, J.; Gross, E.; Dahan, L.; Lacarelle, B.; Mercier, C. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin. Colorectal Cancer, 2010, 9(4), 224-228.
8. Bocci, G.; Danesi, R.; Allegrini, G.; Innocenti, F.; Di Paolo, A.; Falcone, A.; Conte, P.F.; Del Tacca, M. Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. Eur. J. Clin. Pharmacol., 2002, 58(9), 593-595.
9. Di Paolo, A.; Ibrahim, T.; Danesi, R.; Maltoni, M.; Vannozzi, F.; Flamini, E.; Zoli, W.; Amadori, D.; Del Tacca, M. Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. Ther. Drug Monit., 2002, 24(5), 588-593.
10. Di Paolo, A.; Lencioni, M.; Amatori, F.; Di Donato, S.; Bocci, G.; Orlandini, C.; Lastella, M.; Federici, F.; Iannopollo, M.; Falcone, A.; Ricci, S.; Del Tacca, M.; Danesi, R. 5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clin. Cancer Res., 2008, 14(9), 2749-2755.
11. Steimer, J.L.; Vozeh, S.; Racine-Poon, A.; Holford, N.H.G.; O'Neil, R. In: Pharmacokinetics of Drugs, Handbook of Experimental Pharmacology; Welling, P.G.; Balant, L.P. Springer-Verlag: Berlin, 1994; pp 405-451.
12. MATLAB High-performance Numeric Computation and Visualization Software. R2008.a edn. The Math Works, 2008, Natick MA USA.
13. Kowalski, K.G.; Hutmacher, M.M. Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test. J. Pharmacokin. Pharmacodyn., 2001, 28, 253-275.
14. Carlsson, K.C.; Savic, R.M.; Hooker, A.C.; Karlsson, M.O. Modeling subpopulations with the $MIXTURE subroutine: finding the individual probability of belonging to a subpopulation for the use in model analysis improved decision making. AAPS J, 2009, 11(1), 148-154.
15. Holford, N. The Visual Predictive Check. Superiority to Standard Diagnostic (Rorschach) Plots. PAGE Annual Meeting, 2005.
16. Terret, C.; Erdociain, E.; Guimbaud, R.; Boisdron-Celle, M.; McLeod, H.L.; Fety-Deporte, R.; Lafont, T.; Gamelin, E.; Bugat, R.; Canal, P.; Chatelut, E. Dose and time dependencies of 5-fluoro uracil pharmacokinetics. E. Clin. Pharmacol. Ther., 2000 Sep, 68(3), 270-279.
17. Jarugula, V.R.; Lam, S.S.; Boudinot, F.D. Nonlinear Pharmacokinetics of 5-fluorouracil in rats. J. Pharm. Sci., 1997 Jun, 86(6), 756-758.
18. Van Kuilenburg, A.B.P.; Hausler, P.; Schalhorn, A.; Tanck, M.W.T.; Proost, J.H.; Terborg, C.; Behnke, D.; Schwabe, W.; Jabschinsky, K.; Maring, J.G. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin. Pharmacokin., 2012 51(3), 163-174.
19. Sloan, J.A.; Goldberg, R.M.; Sargent, D.J. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J. Clin. Oncol., 2002, 20, 1491-1498.
20. Prado, C.M.M.; Barascos, V.E.; McCargar, L.J.; Mourtzakis, M.; Mulder, K.E. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin. Cancer Res., 2007, 13, 3264-3268.